Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNephrologyHealth Net vadadustat (Vafseo) Coverage Update | O…
    Ask Trek AI about this page
    ModifiedHealth NetPolicy CP PHAR.677

    Clinical Policy: Vadadustat (Vafseo)

    Customize your policy alerts

    Sign up for Health Net Policy CP PHAR.677 alerts

    Get alerted when Policy CP PHAR.677 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, prior authorization and continuation criteria for vadadustat (Vafseo) in adults with anemia due to chronic kidney disease who have been receiving dialysis for at least three months; applies to Health Net lines of business including Commercial, HIM, and Medicaid.

    Policy Summary
    PayerHealth Net
    PolicyVadadustat (Vafseo) for anemia of chronic kidney disease (dialysis-dependent)
    Policy CodePolicy CP PHAR.677
    Change TypeCoding updates, continuation duration extension, step therapy and redirection changes
    Effective DateJun 1, 2024
    Next Review DateMay 25, 2025
    Key ActionSubmit prior authorization with chart notes and lab results documenting dialysis ≥3 months, hemoglobin and iron indices and prior step therapy failure.
    SourceLink
    POLICY UPDATE CHANGES

    Requirement that Vafseo is not prescribed concurrently with Jesduvroq was added.

    Continuation of therapy approval duration extended from 6 to 12 months for Medicaid/HIM.

    HCPCS code JO901 was added and code C9399 was removed from the policy coding appendix.

    Per March SDC, redirection requirement modified to require redirection to both Retacrit and Epogen (if member is unable to use Retacrit).

    Added step therapy bypass for Illinois HIM per IL HB 5395.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Adults on dialysis ≥3 monthsPopulation limited to
    <11 g/dLContinuation Hb threshold
    Ferritin ≥100 or TSAT ≥20%Iron store requirement
    6 monthsInitial approval (commercial)
    12 monthsContinuation for Medicaid/HIM
    JO901HCPCS code added

    Coverage Criteria

    inv-01: Initial Approval Criteria

    Covered when ALL of the following are met:

    Initial criteria group: 1) Diagnosis of anemia due to chronic kidney disease; 2) Age ≥ 18 years; 3) Member has received dialysis for ≥ 3 months; 4) Prescribed by or in consultation with a hematologist or nephrologist; 5) Adequate iron stores as indicated by current (within the last 3 months) serum ferritin ≥ 100 mcg/L or serum transferrin saturation ≥ 20%; 6) Pretreatment hemoglobin level documented; 7) Prior failure of Retacrit (epoetin alfa‑epbx) unless contraindicated, clinically significant adverse effects are experienced, or Retacrit is unavailable, AND prior failure of Epogen (epoetin alfa) unless contraindicated or clinically significant adverse effects are experienced;see nodes

    For Illinois HIM requests, the step therapy requirements do not apply as of 1/1/2026 per IL HB 5395.

    inv-02: Continuation Therapy Criteria

    Continued coverage when ALL of the following are met:

    Continuation criteria group: 1) Member is currently receiving Vafseo via the Centene benefit or has previously met initial approval criteria; 2) Member is responding positively to therapy; 3) Current hemoglobin < 11 g/dL; 4) Adequate iron stores as indicated by current (within the last 3 months) serum ferritin ≥ 100 mcg/L or serum transferrin saturation ≥ 20%; 5) Vafseo is not prescribed concurrently with Jesduvroq;see nodes

    Approval durations: Medicaid/HIM 12 months; Commercial 6 months or to member renewal period, whichever is longer.

    Vafseo (vadadustat) is not indicated for the treatment of anemia due to chronic kidney disease in patients who are not on dialysis. It is also not indicated as a substitute for red blood cell transfusions in patients who require immediate correction of anemia. Requests for uses that are not FDA‑approved are not authorized under this policy unless the provider submits sufficient supporting documentation consistent with applicable off‑label use policies.

    Vafseo must not be prescribed concurrently with Jesduvroq. Concurrent prescription is a policy contraindication and may result in denial of coverage.

    Use of Vafseo for non‑FDA approved indications, including anemia of CKD in patients not on dialysis, is considered off‑label and is not authorized by this policy unless the provider furnishes sufficient evidence of safety and efficacy in accordance with the applicable off‑label use policies (see CP.CPA.09 for Commercial, HIM.PA.154 for Health Insurance Marketplace, and CP.PMN.53 for Medicaid). Absent that documentation, coverage will not be provided for off‑label uses.

    Coding and Product

    Product strengthsmixed
    150 mgTablet strength
    300 mgTablet strength
    450 mgTablet strength
    HCPCS codes referencedHCPCS
    JO901Vadadustat, oral, 1 mg (HCPCS reported as added in policy)
    C9399Unclassified drugs or biologics (HCPCS) — noted as removed from policy
    Serum ferritin or TSAT
    RequirementFerritin ≥ 100 mcg/L OR TSAT ≥ 20% measured within the last 3 months
    TimingLaboratory result must be current (within the last 3 months)
    UseApplies to both initial and continuation coverage criteria
    DocumentationProvider must submit lab results or chart notes demonstrating ferritin or TSAT values
    Hemoglobin for continuation
    Continuation hemoglobin thresholdCurrent hemoglobin < 11 g/dL
    Assessment timing

    Provider Actions and Operational Rules

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Approval durations vary by line of business: Commercial — 6 months or to member's renewal period, whichever is longer; Medicaid/HIM — 6 months (note: continuation approval duration for Medicaid/HIM was extended to 12 months per 2Q 2025 annual review — see Coding Implications/history). Prior authorization may also be required for comparator products (Retacrit, Epogen) when used per step therapy.

    • Commercial approval: 6 months or to member's renewal period, whichever is longer
    • Medicaid/HIM approval: 6 months (continuation duration extended to 12 months in 2Q 2025 update)
    • Prior authorization may be required for Retacrit and Epogen
    Documentation Required

    Required Documentation

    Providers must submit supporting clinical documentation with the prior authorization request. Acceptable documentation includes office chart notes, pertinent lab results (e.g., hemoglobin, serum ferritin, transferrin saturation within the timeframe specified), and consult notes when applicable. Lack of required documentation may result in denial.

    Background

    Vadadustat (brand name Vafseo) is an oral hypoxia‑inducible factor prolyl hydroxylase (HIF‑PH) inhibitor indicated for the treatment of anemia due to chronic kidney disease in adults receiving dialysis for at least three months. It is available in tablet strengths of 150 mg, 300 mg, and 450 mg. The drug carries boxed warnings for increased risks of death, myocardial infarction, stroke, venous thromboembolism, and vascular access thrombosis; these safety considerations should be taken into account when initiating or continuing therapy.

    Definitions

    HIF PH inhibitor
    DefinitionHypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitor: drug class that includes vadadustat (Vafseo)
    MechanismActs on HIF pathway by inhibiting prolyl hydroxylase enzymes (per product class description)
    Indication contextUsed to treat anemia due to chronic kidney disease in adults receiving dialysis (policy context)
    ESA (examples used as step therapy alternatives)
    DefinitionErythropoiesis-stimulating agent (ESA): agents that stimulate red blood cell production
    Step therapy alternativesRetacrit (epoetin alfa-epbx) and Epogen (epoetin alfa) are listed as required alternatives per step therapy
    Policy Summary
    PayerHealth Net
    PolicyVadadustat (Vafseo) for anemia of chronic kidney disease (dialysis-dependent)
    Policy CodePolicy CP PHAR.677
    Change TypeCoding updates, continuation duration extension, step therapy and redirection changes
    Effective DateJun 1, 2024
    Next Review DateMay 25, 2025
    Key ActionSubmit prior authorization with chart notes and lab results documenting dialysis ≥3 months, hemoglobin and iron indices and prior step therapy failure.
    SourceLink
    On This Page
    Coverage CriteriaCoding and ProductProvider Actions and Operational RulesBackgroundDefinitions
    Hemoglobin must be documented at the time of continuation request
    Applies toContinued coverage requests per policy continuation criteria
    DocumentationProvider must submit recent lab results or chart notes showing current hemoglobin
    Continuation approval duration for Medicaid/HIM
    Duration (Medicaid/HIM)12 months
    Duration (Commercial)6 months or to member renewal period (per policy)
    Effective changeContinuation approval for Medicaid/HIM was extended from 6 to 12 months during 2Q 2025 annual review
    Provider noteRefer to policy history and coding appendix for updates when submitting continuation requests
    • Chart notes reflecting diagnosis and treatment rationale
    • Current labs within last 3 months: serum ferritin and transferrin saturation, and hemoglobin values
    • Consultation notes if prescribed in consultation with hematologist or nephrologist
    Denial Risk

    Denial Risk / Triggers

    Denials may be issued if required criteria or documentation are not met. Common denial triggers include: missing or outdated laboratory values, failure to demonstrate prior failure of required step-therapy agents when applicable, requests for concurrent use with contraindicated therapies, or requests for non‑covered indications.

    • Missing chart notes or labs (e.g., ferritin/TSAT not within last 3 months)
    • Failure to document trial/failure of Retacrit (or Epogen when applicable) unless contraindicated or unavailable
    • Concurrent prescribing of Vafseo with Jesduvroq is prohibited and may trigger denial
    • Requests for non‑FDA approved indications without appropriate off‑label documentation per off‑label policies
    Step Therapy

    Step-Therapy and Redirection Requirements

    Step therapy requires redirection to preferred agents unless exceptions apply. Per policy updates, providers must document failure, contraindication, clinically significant adverse effects, or unavailability of Retacrit before approval of Vafseo. If the member is unable to use Retacrit, redirection to Epogen is required (and prior authorization for Epogen may be needed). State-specific exceptions apply — for Illinois HIM requests, step therapy redirection requirements do not apply as of 1/1/2026 per IL HB 5395. Additionally, certain states have oncology redirection prohibitions (see Appendix D).

    • Must document failure of Retacrit unless contraindicated, adverse effects, or shortage/unavailable
    • If unable to use Retacrit, provider must document and redirect to Epogen prior to Vafseo (prior auth for Epogen may be required)
    • IL HIM: step therapy bypass effective 1/1/2026 per IL HB 5395
    • Refer to Appendix D for states and circumstances where redirection/step therapy is prohibited
    Use in policyStep therapy requires failure of Retacrit unless contraindicated; failure of Epogen is also required unless contraindicated
    Vafseo (vadadustat) — product descriptor
    ProductVafseo (vadadustat)
    DescriptionOral hypoxia-inducible factor prolyl hydroxylase inhibitor indicated for anemia of chronic kidney disease in adults on dialysis
    Available strengthsTablets: 150 mg, 300 mg, 450 mg
    ReferencesProduct prescribing information and clinical references cited in policy (Vafseo Prescribing Information; Clinical Pharmacology)